| 2013 |
- Cosmo announces approval of Cortiment™ in the Netherlands.
|
| 2012 |
- Cosmo announces signing of world-wide licensing agreement for CB-03-01 with Medicis.
- Cosmo announces acceptance of NDA filing by FDA for Uceris® in February.
|
| 2011 |
- Cosmo announces filing of NDA for Uceris® (Budesonide MMX) in the USA in December.
- Cosmo announces data for extension study for Budesonide MMX I nthe US.
- Cosmo announces the additional approval of LIALDA in the U.S. for the maintenance of remission in patients with ulcerative colitis.
- Cosmo announces filing of MAA for Cortiment® (Budesonide MMX) in the EU in May.
- Cosmo announces very positive results of the first parts of the phase II clinical trials following the live transmission of Blu-Colonoscopy at the International Meeting for Advanced Gastroenterology Endoscopy at Humanitas Hospital in Milano.
- Cosmo announces live transmission of Blu-Colonoscopy at the International Meeting for Advanced Gastroenterology Endoscopy at Humanitas Hospital in Milano.
|
| 2010 |
- Cosmo announces successful results of phase III trials for Budesonide MMX® in the EU.
- Cosmo announces successful results of phase III trials for Budesonide MMX® in the US.
- Cosmo announces delisting of BioXell.
- Cosmo announces final results of its tender offer for BioXell.
- Cosmo Pharmaceuticals announces preliminary interim result of its tender offer for BioXell.
|
| 2009 |
- Cosmo's CB-03-01 phase II pilot study in acne demonstrates superiority over Retin A® on 11 December.
- Cosmo publishes the public tender offer to acquire BioXell on 8 December.
- Cosmo offers to acquire BioXell on 18 November.
|
| 2008 |
- Strategic collaboration with Santarus for U.S rights to Budesonide MMX® and Rifamycin MMX® on 15 December.
- Licensing agreement with Dr. Falk for Rifamycin SV MMX®.
- Cosmo awarded US patent for use of its MMX® technology.
|
| 2007 |
- UK Market launch of Mezavant XL® by Shire plc on 05 November.
- Licensing agreement with Ferring for Budesonide MMX®.
- US Market launch of Lialda® by Shire plc on 19 March.
- IPO on the Swiss Stock Exchange (SWX) on 12 March.
|
| 2006 |
- FDA approval for the manufacturing of tablets to the USA.
- Completion of 2.000 sq m plant in Lainate, Milan.
|
| 2005 |
- Completion of first financing round of €20.4 million by Cosmo Holding S.p.A.
- Lialda®/Mezavant® Supply Agreement with Shire plc.
|
| 2004 |
- Opening of an R&D laboratory in Catania, Italy.
|
| 2001 |
- Lialda®/Mezavant® globally out-licensed to Giuliani S.p.A./ Shire plc*.
|
| 1999 |
- Filing of the first MMX® Multi Matrix technology patent for the controlled release of tablets in the gastro-intestinal tract.
|
| 1998 |
- Strategic decision to develop novel oral formulations of off-patent pharmaceutical products to generate new patentable applications.
|
| 1997 |
- Foundation of Cosmo S.p.A. by purchasing contract manufacturing unit in Lainate (Milan) from Parke Davis (now Pfizer Group).
|